These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35978507)

  • 1. Type 1 diabetes with immune checkpoint inhibitors: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.
    Zhu J; Luo M; Liang D; Gao S; Zheng Y; He Z; Zhao W; Yu X; Qiu K; Wu J
    Int Immunopharmacol; 2022 Sep; 110():109053. PubMed ID: 35978507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Facial palsy induced by immune checkpoint blockade: A systematic analysis of clinical trials and a pharmacovigilance study of postmarketing data.
    Zhu J; Li J; Zheng Y; Gao S; He Z; Qiu K; Yu X; Wu J
    Int Immunopharmacol; 2023 Dec; 125(Pt B):111184. PubMed ID: 37952483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
    Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system.
    Liang X; Xiao H; Li H; Chen X; Li Y
    Front Immunol; 2024; 15():1396752. PubMed ID: 38745663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
    Wang H; Yang H; Zhou X; Zhang X
    Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
    Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
    Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemorrhage profile associated with immune checkpoint inhibitors: a systematic review and a real-world study based on the FAERS database.
    Chen M; He Z; Zhu J; Yang S; Gao S; Wu J; Ren H; Liang D; Jiang W; Zou Y; Yu X; Wu J
    Expert Opin Drug Saf; 2024 Apr; 23(4):497-511. PubMed ID: 38556702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stevens-Johnson syndrome/toxic epidermal necrolysis in patients treated with immune checkpoint inhibitors: A safety analysis of clinical trials and FDA pharmacovigilance database.
    Zhu J; Chen G; He Z; Zheng Y; Gao S; Li J; Ling Y; Yu X; Qiu K; Wu J
    EClinicalMedicine; 2021 Jul; 37():100951. PubMed ID: 34386743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
    Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
    Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
    Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
    J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
    Wang F; Wu X
    J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
    Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of uveitis events in real-world patients receiving immune checkpoint inhibitors based on the FAERS database.
    Fan Q; Chen H; Hu Y; Zhao B
    Cutan Ocul Toxicol; 2023 Jun; 42(2):68-73. PubMed ID: 37130046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
    Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database.
    Fu Z; Liu J; Zhang C; Hu H; Li S; Zhang Y; You R
    Front Pharmacol; 2024; 15():1383212. PubMed ID: 38948476
    [No Abstract]   [Full Text] [Related]  

  • 18. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
    Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN
    Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
    Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
    J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
    Xu Y; Yan C; Zhao Y; Li D; Guo M; Cui X
    Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.